Drugs in Dev. Immunology
Phase IV
Lead Product(s) : Adalimumab-bwwd
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Organon
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : HADLIMA (Adalimumab-bwwd) is a biosimilar product of HUMIRA®, formulated for the treatment of rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritisetc. The drug bind specifically to TNF-alpha and block its interaction with the p55 and p...
Brand Name : Hadlima
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 01, 2023
Lead Product(s) : Adalimumab-bwwd
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Organon
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Teprotumumab
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Tepezza (teprotumumab-trbw) binds to insulin-like growth factor-1 receptor (IGF-1R) and blocks its activation and signaling. It is being investigated in patients with thyroid eye disease.
Brand Name : Tepezza
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 10, 2023
Lead Product(s) : Teprotumumab
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Guselkumab
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TREMFYA (guselkumab) is a fully human monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is an important driver of the pathogenesis of inflammatory diseases.
Brand Name : Tremfya
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 10, 2022
Lead Product(s) : Guselkumab
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Teprotumumab
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Tepezza, (teprotumumab-trbw) first medicine approved by FDA for treatment of TED, among thousands of patients included in this 19-month new post-marketing Safety analysis, approximately 10% of all cases reported to safety database have included a hearing...
Brand Name : Tepezza
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 15, 2022
Lead Product(s) : Teprotumumab
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Baricitinib
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Incyte Corporation
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Among those treated with OLUMIANT, the overall incidence rate of adverse events per 100 patient years of exposure was 22.6, and the incidence rate of serious adverse events was 7.4. Incidence rates remained stable over time across the 14,744 patient year...
Brand Name : Olumiant
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 09, 2021
Lead Product(s) : Baricitinib
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Incyte Corporation
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tofacitinib Citrate
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Health Canada is informing Canadians and health care professionals that it is conducting a safety review of Xeljanz and Xeljanz XR (tofacitinib) after a clinical trial identified an increased risk of serious heart-related issues and cancer in trial parti...
Brand Name : Xeljanz
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 06, 2021
Lead Product(s) : Tofacitinib Citrate
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Tofacitinib Citrate
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The co-primary endpoints of this study were non-inferiority of tofacitinib compared to TNFi in regard to major adverse cardiovascular events (MACE) and malignancies (excluding non-melanoma skin cancer (NMSC)).
Brand Name : Xeljanz
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 31, 2021
Lead Product(s) : Tofacitinib Citrate
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Teprotumumab,rHuPH20
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Horizon Therapeutics
Deal Size : $190.0 million
Deal Type : Collaboration
Details : Horizon intends to use ENHANZE® to develop a SC formulation of TEPEZZA (teprotumumab-trbw), indicated for the treatment of Thyroid Eye Disease.
Brand Name : Tepezza
Molecule Type : Large molecule
Upfront Cash : $30.0 million
November 23, 2020
Lead Product(s) : Teprotumumab,rHuPH20
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Horizon Therapeutics
Deal Size : $190.0 million
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?
Reset All
